These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2439947)

  • 1. Clinical and biochemical correlates of bradyphrenia in Parkinson's disease.
    Mayeux R; Stern Y; Sano M; Cote L; Williams JB
    Neurology; 1987 Jul; 37(7):1130-4. PubMed ID: 2439947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism.
    Stern Y; Mayeux R; Côté L
    Arch Neurol; 1984 Oct; 41(10):1086-9. PubMed ID: 6206831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
    Gibson CJ; Logue M; Growdon JH
    Arch Neurol; 1985 May; 42(5):489-92. PubMed ID: 2581531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective attention in Alzheimer's disease: CSF correlates of behavioral impairments.
    Freed DM; Corkin S; Growdon JH; Nissen MJ
    Neuropsychologia; 1988; 26(6):895-902. PubMed ID: 2461537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia.
    Corona GL; Cucchi ML; Frattini P; Santagostino G; Schinelli S; Romani A; Pola A; Zerbi F; Savoldi F
    Eur Arch Psychiatry Neurol Sci; 1989; 239(2):79-86. PubMed ID: 2478368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central amine metabolism in Alzheimer's disease: in vivo relationship to cognitive deficit.
    Mann JJ; Stanley M; Neophytides A; de Leon MJ; Ferris SH; Gershon S
    Neurobiol Aging; 1981; 2(1):57-60. PubMed ID: 7266742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered serotonin metabolism in depressed patients with parkinson's disease.
    Mayeux R; Stern Y; Cote L; Williams JB
    Neurology; 1984 May; 34(5):642-6. PubMed ID: 6200801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia.
    Palmer AM; Sims NR; Bowen DM; Neary D; Palo J; Wikstrom J; Davison AN
    J Neurol Neurosurg Psychiatry; 1984 May; 47(5):481-4. PubMed ID: 6204017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher cerebrospinal fluid MHPG in subjects with dementia of the Alzheimer type. Relationship with cognitive dysfunction.
    Sheline YI; Miller K; Bardgett ME; Csernansky JG
    Am J Geriatr Psychiatry; 1998; 6(2):155-61. PubMed ID: 9581211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain metabolism in Alzheimer's dementia: studies of 11C-deoxyglucose accumulation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects.
    Nybäck H; Nyman H; Blomqvist G; Sjögren I; Stone-Elander S
    J Neurol Neurosurg Psychiatry; 1991 Aug; 54(8):672-8. PubMed ID: 1719135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychological deficits associated with driving performance in Parkinson's and Alzheimer's disease.
    Grace J; Amick MM; D'Abreu A; Festa EK; Heindel WC; Ott BR
    J Int Neuropsychol Soc; 2005 Oct; 11(6):766-75. PubMed ID: 16248912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of biogenic amine levels in the Rett syndrome.
    Zoghbi HY; Percy AK; Glaze DG; Butler IJ; Riccardi VM
    N Engl J Med; 1985 Oct; 313(15):921-4. PubMed ID: 2412119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.
    González-Quevedo A; García JC; Fernández R; Fernández Cartaya L
    Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease and dementia: clinical and neurochemical correlations.
    Strittmatter MM; Cramer H
    Neuroreport; 1992 May; 3(5):413-6. PubMed ID: 1378766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Concentrations of monoamines and monoamine metabolites in cerebrospinal fluid determined by high-performance liquid chromatography with electrochemical detection].
    Yoshino K
    No To Shinkei; 1982 Nov; 34(11):1099-106. PubMed ID: 6186264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases.
    Gnanalingham KK; Byrne EJ; Thornton A; Sambrook MA; Bannister P
    J Neurol Neurosurg Psychiatry; 1997 Mar; 62(3):243-52. PubMed ID: 9069479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid biopterin is decreased in Alzheimer's disease.
    Kay AD; Milstien S; Kaufman S; Creasey H; Haxby JV; Cutler NR; Rapoport SI
    Arch Neurol; 1986 Oct; 43(10):996-9. PubMed ID: 2428341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
    N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Amine metabolites in cerebrospinal fluids and thyrotropin releasing hormone in spinocerebellar degeneration].
    Arai M
    Rinsho Shinkeigaku; 1988 Jun; 28(6):595-604. PubMed ID: 2466598
    [No Abstract]   [Full Text] [Related]  

  • 20. Simultaneous determination of the three major monoamine metabolites in CSF by HPLC with electrochemical detection.
    Van Bockstaele M; Dillen L; Claeys M; De Potter WP
    Arch Int Pharmacodyn Ther; 1982 Dec; 260(2):304-5. PubMed ID: 6187306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.